DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.
NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in...
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transaction. Roivant Sciences Ltd., the Company’s controlling stockholder, has agreed to purchase shares in the offering. All of the shares are to be sold by Immunovant.
(NASDAQ:IMVT) NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared an abstract with six-month off-treatment data in uncontrolled Graves’ disease (GD) patients treated with batoclimab for 24 weeks, to be presented at the 2025 Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025.
(NASDAQ:IMVT) NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared an abstract with six-month off-treatment data in uncontrolled Graves’ disease (GD) patients treated with batoclimab for 24 weeks, to be presented at the 2025 Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025.
(NASDAQ:IMVT) NEW YORK and NEW ORLEANS, Aug. 29, 2025 /PRNewswire/ -- The law firm of Kahn Swick & Foti, LLC ("KSF") has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) ("Immunovant"). KSF is investigating whether Immunovant's officers and/or directors breached their fiduciary duties...
LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s officers and/or directors breached their fiduciary duties or otherwise violated state or federal laws. If you hold shares of Immunovant, Inc. (NasdaqGS: IMVT), we urge you to contact KSF to discuss your legal rights, without obligation or cost to you, by calling KSF toll-fr
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for the quarter ended June 30, 2025.
Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402.
